ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Extent of Coronary Artery Disease and Clinical Outcomes With Ticagrelor Monotherapy Versus Aspirin After Coronary Artery Bypass Grafting: Insights From the TiCAB Trial

Thursday, July 10, 2025

Submitted by

Mujtaba Mubashir

Source

Source Name: European Journal of Cardio-Thoracic Surgery

Source URL: https://academic.oup.com/ejcts/article/67/7/ezaf175/8145572

Author(s)

Melanie Arnreiter, Moritz von Scheidt, Johannes M Albes, Tim Attmann, Andreas Boening, Yeong-Hoon Choi, Lenard Conradi, Bernhard C Danner, Andreas Fach, Ivar Friedrich, Herko Grubitzsch, Roland Heck, Alexander Joost, Christoph Knosalla, Martin Misfeld, Martin Oberhoffer, Julia Riebandt, Andreas Schaefer, Matthias Siepe, Thomas Walther, Gerhard Wimmer-Greinecker, Uwe Zeymer, Heribert Schunkert, Adnan Kastrati, Sigrid Sandner

This article highlights the results from the Ticagrelor in CABG (TiCAB) trial, which examined the use of Ticagrelor monotherapy in coronary artery bypass grafting (CABG) compared to aspirin. This study involved 752 patients. The authors found no significant difference in major adverse cardiac and cerebrovascular events (MACCE) between the aspirin and Ticagrelor groups, even when stratified for different complexity levels of coronary disease based on SYNTAX scores.